10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)

8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)

EFFECT - DiaMedica Therapeutics Inc. (0001401040) (Filer)

424B3 - DiaMedica Therapeutics Inc. (0001401040) (Filer)

S-3 - DiaMedica Therapeutics Inc. (0001401040) (Filer)

D - DiaMedica Therapeutics Inc. (0001401040) (Filer)

8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic

Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee. Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009. Before joining Medtronic, he was

DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinica

Leadership Team Continues to Expand with Addition of Key Leader in Clinical Operations DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations. Ms. Daves, a recognized leader in managing global clinical studies, has significant experience in all phases of clinical development and will complement DiaMedica's growing clinical team. "Julie brings nearly two decades of clinical development operations experience to DiaMedica across a wide breadth

Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini

Leadership Team Continues to Expand with Addition of Veteran Genentech Executive DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Dominic Cundari as Chief Commercial Officer. In this role, Mr. Cundari will be focused primarily on the commercial planning, positioning and launch preparations for DM199 in acute ischemic stroke. "Dom has extensive experience in successfully launching specialty biopharmaceuticals and was instrumental in building the Activase® (tPA) franchise at Genentech and changing the standard of care for ischemic str

Executive with Extensive Track Record in Neurology and Rare Disease Drug Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine and drug development in large and small biopharmaceutical companies. "We are delighted to welcome Dr. Gruis to the DiaMedica team as Chief Medical Officer," said Rick Pauls, CEO of DiaMedica. "Dr. Gruis has deep experience in neurology drug development and regu

Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM CentralWhite Paper: The Potential of DM199 to Treat PreeclampsiaDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.

- SEC Filing

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement agent was not used in connection with this private placement.Pursuant to the terms of the securities purchase agreements, the Company will issue a total of 4,720,000 common shares at a purchase price of $2.50 per share. The private placement is expected to close on or about June 28, 2024, subject to the satisfaction of

 Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024Key Proof-of-Concept Results Expected in the First Half of 2025Management will Host a Conference Call Thursday, June 27, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to Discuss PreeclampsiaCompany to Host Preeclampsia Key Opinion Leader Event July 29, 2024DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia. Preeclampsia

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 30 percent increase over losses of $(0.20) per share from the same period last year.

Craig-Hallum analyst Alexander Nowak assumes DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Target of $8.

Craig-Hallum analyst Alexander Nowak maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and lowers the price target from $11 to $8.

Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and lowers the price target from $7 to $6.

Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica's investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data for Part 1A in the first half of 2025 which is expected to demonstrate initial proof-of-concept including whether DM199 is safe and lowers blood pressure. Additionally, for patients with early onset PE, DiaMedica will be looking for improvements in uterine artery dilation, indicating that DM199 therapy is potentially disease modifying in these patient

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day. Investors and attendees that would like to schedule a meeting with DiaMedica's management can contact their Craig-Hallum representative to arrange a meeting. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the liv

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 14, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/8B2w698qkyb Dial In: (646) 357-8785 Conference ID: 28056 Interested parties may access the conf

Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has issued approval to proceed with the planned two-part Phase 2 study, which will be conducted as an investigator-sponsored trial at Tygerberg Hospital

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, announced today that management will be participating in the following investor conferences during September. HC Wainwright Global Investment Conference, September 9-11, New York – Management will present in person on Monday, September 9th at 3:00-3:30 PM ET and participate in one-on-one meetings. Lake Street Best Ideas Growth Conference Big 8, September 12, New York – Management will participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting

Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, A

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2024 financial results will be released after the markets close on Wednesday, August 7th. DiaMedica will host a live conference call on Thursday, August 8th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, August 8, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/RzlwnM9ne8E Dial In: (646) 357-8785 Conference

Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics. The webinar will feature Prof. Stephen Tong, MD, PhD (The Uni

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximately 4.7 million common shares at a purchase price of $2.50 per share, a premium of approximately 10% above the Company's per share closing price on Tuesday June 25, 2024. After deducting estimated offering expenses, the Company received net proceeds of approximately $11.7 million. The Company reported cash, cash equivalents and short-term investments of $46.5 million as of March 31, 2024. On a pro fo

4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)